ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $2.21B

      Shares

      15.8M

      % of Portfolio

      1.61%

      Average Buy Price

      $170

      Avg closing price
      Price range

      50 PRIMECAP Management Biogen Trades

      PRIMECAP Management's position in Biogen is currently worth $2.21B. That's 1.61% of their equity portfolio (16th largest holding). The investor owns 11.41% of the outstanding Biogen stock. The first Biogen trade was made in Q1 2013. Since then PRIMECAP Management bought shares twelve more times and sold shares on 37 occasions. The investor's estimated purchase price is $2.69B, resulting in a loss of 18%.

      Avg closing price
      Price range
      Sold 0.9% shares (-141k shares) Q2 2025
      Avg closing price $124.57
      Price range $113.38 - $135.49
      Sold 0.6% shares (-103k shares) Q1 2025
      Avg closing price $142.96
      Price range $133.43 - $153.27
      Sold 1.6% shares (-269k shares) Q4 2024
      Avg closing price $167.98
      Price range $146.06 - $191.56
      Sold 0.1% shares (-23.2k shares) Q3 2024
      Avg closing price $209.38
      Price range $189.07 - $236.80
      Increased shares by 0.7% (+118k shares) Q2 2024
      Avg closing price $217.32
      Price range $190.52 - $236.72
      Sold 0.3% shares (-43.8k shares) Q1 2024
      Avg closing price $234.20
      Price range $212.02 - $267.71
      Increased shares by 1.6% (+252k shares) Q4 2023
      Avg closing price $245.62
      Price range $222.59 - $267.94
      Sold 0.1% shares (-13.3k shares) Q3 2023
      Avg closing price $267.47
      Price range $253.30 - $285.89
      Increased shares by 0.2% (+24.7k shares) Q2 2023
      Avg closing price $297.68
      Price range $275.25 - $318.06
      Increased shares by 1.9% (+301k shares) Q1 2023
      Avg closing price $276.70
      Price range $256.56 - $292.34
      Sold 0.3% shares (-41.1k shares) Q4 2022
      Avg closing price $282.44
      Price range $253.67 - $306.72
      Increased shares by 0.1% (+15.2k shares) Q3 2022
      Avg closing price $212.38
      Price range $194.69 - $276.61
      Sold 0.7% shares (-108k shares) Q2 2022
      Avg closing price $204.43
      Price range $187.54 - $223.02
      Increased shares by 0.5% (+77.2k shares) Q1 2022
      Avg closing price $217.46
      Price range $193.77 - $244.14
      Sold 3.1% shares (-502k shares) Q4 2021
      Avg closing price $257.12
      Price range $223.92 - $287.77
      Sold 1.2% shares (-200k shares) Q3 2021
      Avg closing price $327.75
      Price range $282.99 - $369.05
      Sold 1.8% shares (-300k shares) Q2 2021
      Avg closing price $302.94
      Price range $259.00 - $414.71
      Increased shares by 5.9% (+936k shares) Q1 2021
      Avg closing price $269.69
      Price range $242.95 - $284.63
      Increased shares by 0.8% (+125k shares) Q4 2020
      Avg closing price $257.97
      Price range $236.26 - $355.63
      Increased shares by 0.4% (+64.8k shares) Q3 2020
      Avg closing price $278.91
      Price range $264.77 - $305.71

      News about Biogen Inc and PRIMECAP Management

      Should You Be Confident in Biogen (BIIB)?

      Should You Be Confident in Biogen (BIIB)?

      Patient Capital Management, a value investing firm, released its ¡°Patient Capital Opportunity Equity Strategy¡± first quarter 2024 investor letter. A copy of ...

      Insider Monkey Insider Monkey, over 1 year ago
      Boston Common Asset Management LLC Boosts Holdings in Biogen Inc. (NASDAQ:BIIB)

      Boston Common Asset Management LLC Boosts Holdings in Biogen Inc. (NASDAQ:BIIB)

      Boston Common Asset Management LLC lifted its stake in Biogen Inc. (NASDAQ:BIIB ¨C Free Report) by 62.3% during the third quarter, according to its most recen...

      The AM Reporter The AM Reporter, over 1 year ago
      Morningstar Investment Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB)

      Morningstar Investment Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB)

      Morningstar Investment Management LLC purchased a new position in Biogen Inc. (NASDAQ:BIIB ¨C Free Report) during the 2nd quarter, according to its most recen...

      The AM Reporter The AM Reporter, over 1 year ago
      Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)

      Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)

      Biogen Inc. (NASDAQ:NASDAQ:BIIB) Decentralized Clinical Trials in Focus Conference September 26, 2023 10:00 AM ETCompany ParticipantsStephanie Manson Brown -...

      Seeking Alpha Seeking Alpha, almost 2 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×